Based on the Vita Life Sciences Ltd stock forecast from 0 analysts, the average analyst target price for Vita Life Sciences Ltd is not available over the next 12 months. Vita Life Sciences Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Vita Life Sciences Ltd is Bullish , which is based on 12 positive signals and 4 negative signals. At the last closing, Vita Life Sciences Ltd’s stock price was AUD 2.17. Vita Life Sciences Ltd’s stock price has changed by -5.24% over the past week, -5.24% over the past month and +28.40% over the last year.
No recent analyst target price found for Vita Life Sciences Ltd
No recent average analyst rating found for Vita Life Sciences Ltd
Company Overview Vita Life Sciences Ltd
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children's health; antioxidants; bones, joints, and muscles; and eye health. The company markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia. Read Less
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In ...Read More
Frequently Asked Questions About Vita Life Sciences Ltd (VLS:AU) Stock
Stock Target Advisor's fundamental analysis for Vita Life Sciences Ltd's stock is Bullish .
VLS:AU stock's dividend yield is 3.23%.
Our analysis grades VLS:AU stock's dividend yield at A+. This means that VLS:AU stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this VLS:AU may be a good dividend stock for its sector.
Unfortunately we do not have enough data on VLS:AU's stock to indicate what its average analyst target is.
VLS:AU stock's Price/Earning ratio is 12.76.
Our analysis grades VLS:AU stock's Price / Earning ratio at D+. This means that VLS:AU stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this VLS:AU may be fairly valued for its sector
The last closing price of VLS:AU's stock was AUD 2.17.
The most recent market capitalization for VLS:AU is AUD 0.12B.
Unfortunately we do not have enough analyst data on VLS:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Vita Life Sciences Ltd's stock.
As per our most recent records Vita Life Sciences Ltd has 0 Employees.
Vita Life Sciences Ltd's registered address is Bath Road, Kirrawee, NSW, Australia, 2232.
You can get more information about it from Vita Life Sciences Ltd's website at https://vitalifesciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Vita Life Sciences Ltd (VLS:AU) Stock
Stock Target Advisor's fundamental analysis for Vita Life Sciences Ltd's stock is Bullish .
VLS:AU stock's dividend yield is 3.23%.
Our analysis grades VLS:AU stock's dividend yield at A+. This means that VLS:AU stock's dividend yield is above 100% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this VLS:AU may be a good dividend stock for its sector.
Unfortunately we do not have enough data on VLS:AU's stock to indicate what its average analyst target is.
VLS:AU stock's Price/Earning ratio is 12.76.
Our analysis grades VLS:AU stock's Price / Earning ratio at D+. This means that VLS:AU stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the AU exchange.
Based on this VLS:AU may be fairly valued for its sector
The last closing price of VLS:AU's stock was AUD 2.17.
The most recent market capitalization for VLS:AU is AUD 0.12B.
Unfortunately we do not have enough analyst data on VLS:AU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Vita Life Sciences Ltd's stock.
As per our most recent records Vita Life Sciences Ltd has 0 Employees.
Vita Life Sciences Ltd's registered address is Bath Road, Kirrawee, NSW, Australia, 2232.
You can get more information about it from Vita Life Sciences Ltd's website at https://vitalifesciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VLS:AU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
